Paritaprevir

A HCV NS3/4A protease inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
2mg

￥762.00

610.00

- +
5mg

￥1412.00

1130.00

- +
10mg

￥2262.00

1810.00

- +
50mg

￥6725.00

5380.00

- +
100mg

￥10800.00

8640.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci22792
CAS: 1216941-48-8
别名: ABT-450; Veruprevir
分子式: C40H43N7O7S
分子量: 765.88
纯度: >98%
溶解度: DMSO : ≥ 125 mg/mL (163.21 mM);Water : < 0.1 mg/mL (insoluble)
储存: 4°C, away from moisture and light
库存: 现货

Background

Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively.

Paritaprevir demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a[2].

The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1].

参考文献:
[1]. Smith MA,et al. Profile ofparitaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther.2015 Nov 13;9:6083-94.
[2]. Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15.